If you’ve been following lipid management guidelines, you’ve probably heard about PCSK9 inhibitors, the “miracle drugs” that cut LDL-C by 50-60%. Repatha, Praluent, and the newer siRNA agent inclisiran have transformed cardiovascular prevention.
So here’s the uncomfortable question to ask: What if this entire therapeutic strategy was optimized for the wr…
